Trials / Withdrawn
WithdrawnNCT02826642
A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
A Phase I, Open Label, Multicenter, Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and potential efficacy of IDH305 with standard treatments for newly diagnosed IDH1R132 mutant acute myeloid leukemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDH305 |
Timeline
- Start date
- 2016-08-26
- Primary completion
- 2016-11-29
- Completion
- 2016-11-29
- First posted
- 2016-07-11
- Last updated
- 2019-04-10
Source: ClinicalTrials.gov record NCT02826642. Inclusion in this directory is not an endorsement.